Last reviewed · How we verify
NCT03381079
Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia
Phase 2 trial testing Posterior scleral reinforcement in High Myopia in 120 participants. Status unknown.
1 October 2020
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 April 2018 |
| Primary completion | 1 October 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- Posterior scleral reinforcement
Conditions studied
- High Myopia — all drugs for High Myopia →
- Posterior Scleral Reinforcement — all drugs for Posterior Scleral Reinforcement →
- Adults — all drugs for Adults →
- Axial Elongation — all drugs for Axial Elongation →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 40, any sex, with High Myopia or Posterior Scleral Reinforcement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of posterior scleral reinforcement on controlling myopia progression, including change in refraction, axial elongation as well as sight-threatening complications, in adults with high myopia. Half the adults will receive posterior scleral reinforcement, while the other half will receive no surgerical treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03381079
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for High Myopia
Currently open trials in the same condition.
- NCT07052825 — The Role of Capsular Tension Rings in Intraocular Lens Stability in High Myopia Cataract Patients: A Prospective Self-Co · NA · recruiting
- NCT06264830 — 3D Visualization System in Highly Myopic Cataract Operation · NA · recruiting
- NCT06162234 — Wuhan High Myopia Study · recruiting
- NCT05850936 — Effect of IOP Lowering on Progressive HM · NA · active not recruiting
- NCT05550740 — Repeated Low-Level Red-Light Therapy for Shortening Axial Length · NA · active not recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03381079 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 22 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381079.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing